

Keystone eSymposium: "Precision Engineering
of the Genome, Epigenome and Transcriptome"



In Vivo Gene Editing of Hematopoietic Stem and Progenitor Cells

Sean Burns, M.D.


March 10, 2021

Gene editing holds great promise for treating hereditary blood disorders

Sickle cell disease (SCD)



- Major global health issue impacting millions, caused by a mutation in the beta globin gene
- Characterized by severe pain and multi-organ injury with reduced life expectancy and quality of life
- Traditional treatments are limited; allogeneic hematopoietic stem cell (HSC) transplantation is reserved as a last resort for severely affected patients

→ ***Ex vivo* gene editing of autologous HSCs recently demonstrated benefit for SCD in a clinical trial**



Ex vivo SCD gene editing still has significant limitations

Complex cell manufacturing process



Conditioning regimen toxicity


- Immunosuppression for > 1 month, predisposing to infection
- Risk of malignancy from chemotherapy drugs, especially leukemia
- Risk of infertility

Implications

- *Ex vivo* gene editing will be limited to highly selected SCD patients with severe disease
- Treatment complexity will limit access for patients in resource-poor settings

In vivo non-viral SCD gene editing could overcome these limitations

Simplified process



Improved safety and accessibility


- Avoids myeloablation and associated risks of immunosuppression, malignancy, and infertility
 - Approach could become mainstream therapy for SCD
- Avoids need for complex cell manufacturing or extensive supportive care post-treatment
 - Treatment simplicity could expand access to patients in resource-poor settings

Desired features of *in vivo* approach

- Provides clinically meaningful, durable HSC editing
- Allows for multidosing to reach therapeutic target
- Preserves regenerative potential of edited cells
- Translatable to human HSC population

Intellia's modular *in vivo* editing platform employs non-viral LNP delivery

Lipid Nanoparticles



gRNA target site specificity
defined by 20mer at 5' end


Transient Cas9
expression from mRNA

Key Advantages of LNP Delivery

- ✓ Large cargo capacity
- ✓ Biodegradable / transient expression
- ✓ Low immunogenicity
- ✓ Redosing capability
- ✓ Scalable synthetic manufacturing
- ✓ Tunable tropism


Editing HSCs *in vivo* requires LNPs with bone marrow tropism

- LNPs designed, formulated, and tested *in vivo* to identify compositions with enhanced delivery to bone marrow and HSCs



Bone marrow-tropic LNP enables editing of mouse bone marrow as well as hematopoietic stem and progenitor cells (HSPCs)

- Dose dependent editing at 1 week post dosing in whole bone marrow and HSPC populations
- Levels predicted to have therapeutic benefit if achieved in patients with SCD




* *Blood*. 2017;130(17):1946-1948.

** Lin⁺Sca-1⁺c-Kit⁺ (LSK) cell population


Editing of mouse bone marrow and HSCs is durable through at least one year

- Editing was similar across all time points assessed, in both whole bone marrow and HSCs populations
- Results highlight the potential for a single-course, long-lasting therapy



Editing of mouse bone marrow and HSCs increases with multidosing

- Non-immunogenic LNP delivery platform may enable stepwise “treat-to-target” approach



* *Blood*. 2017;130(17):1946-1948.


** Lin⁻Sca-1⁺c-Kit⁺CD34⁺Flk2⁻ cell population

Edited HSCs retain their capacity to reconstitute primary hematopoietic lineages


In a competitive transplant model using mice treated with a single dose of LNP, edited cells:

- ✓ Remained stable as a percentage of the bone marrow and HSC populations over a 14-week period
- ✓ Reconstituted healthy bone marrow with normal production of lymphoid and myeloid lineages

→ **Nonviral approach preserves normal stem and progenitor cell function in mice**





Normal Lineage Distribution



Nonviral CRISPR/Cas9 delivery supports editing of human HSPCs in mice

- Single *in vivo* dose of LNP achieved clinically significant level of editing in human CD34+ cells
- Results suggest cross-species relevance of LNP platform for genome engineering of HSPCs



Note: guide "C" used in this experiment

Key Takeaways

- LNPs well suited to deliver CRISPR/Cas9 to hematopoietic cells for durable *in vivo* gene editing
- Achieved clinically relevant levels of HSC editing in wild-type mice
- Multidosing of LNPs increased editing in stepwise manner, potentially enabling “treat-to-target” therapeutic approach
- Edited cells retain regenerative potential and reconstitute primary hematopoietic lineages
- Achieved therapeutically relevant levels of editing of human CD34+ cells in a xenotransplant mouse model, highlighting cross-species translation

Next step: Demonstrate relevance to future clinical application by confirming activity in nonhuman primate model

Intellia

THERAPEUTICS